Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab.
Baxter NN, Fischer HD, Richardson DP, Urbach DR, Bell CM, Rochon P, Brade A, Earle CC. Baxter NN, et al. Dis Colon Rectum. 2018 Mar;61(3):306-313. doi: 10.1097/DCR.0000000000000966. Dis Colon Rectum. 2018. PMID: 29420426
BACKGROUND: Patients receiving Bevacizumab, a vascular endothelial growth factor inhibitor used to treat metastatic colorectal cancer, may be at greater risk of complications after colorectal surgery because of impaired healing. OB …
BACKGROUND: Patients receiving Bevacizumab, a vascular endothelial growth factor inhibitor used to treat metastatic …
Does the Presence of an Intact Primary Increase the Risk of Non-Elective Colorectal Surgery in Patients Treated with Bevacizumab?
Baxter NN, Sutradhar R, Dossa F, Fu L, Rochon P, Wei AC, Kennedy ED, Earle CC. Baxter NN, et al. Colorectal Dis. 2020 Aug 7. doi: 10.1111/codi.15294. Online ahead of print. Colorectal Dis. 2020. PMID: 32767608
AIM: In patients with incurable metastatic colorectal cancer (mCRC), primary tumour resection is debated; however, patients with intact primaries may be at higher risk of complications requiring surgery when receiving treatment with be
AIM: In patients with incurable metastatic colorectal cancer (mCRC), primary tumour resection is debated; however, patients
Feedback